Purpose To assess the prognostic impact of TP53 mutations in EGFR-mutant advanced
NSCLC patients treated with TKIs. Methods Studies exploring the clinical outcomes of EGFR …

Non-small cell lung cancer (NSCLC) is the most common cause of cancer death worldwide.
In non-squamous NSCLC, the identification of oncogenic drivers and the development of …

Actionable mutations refer to DNA alterations that, if detected, would be expected to affect
patients' response to treatments [1]. Among these actionable mutations, the most clinically …

Background The incidence of lung cancer in the US has been decreasing but a bigger
decline has been observed in men despite similar declines in tobacco use between men …

Background Small bowel cancer (SBC) is a very rare solid malignancy. Consequently,
compared with other malignant gastrointestinal tumors, our knowledge regarding SBC …

Co-occurring genetic alterations in solid tumors are a critical and influential prognostic factor
that holds substantial importance in understanding the disease progression and guiding …

Background Tyrosine kinase inhibitors (TKIs) have changed the treatment landscape for
patients with advanced non-small cell lung cancer (NSCLC) found to have oncogene-driven …

Despite the unprecedented rapid advances in cancer therapeutics development, drug
resistance remains a clinical challenge in precision oncology. Resistance is diverse at …

Background: Gaining a better understanding of molecular alterations in the pathogenesis of
lung cancer reveals a significant change in approach to the management and prognosis of …